Recent Results of Clinical Therapeutic Trials for Gastrointestinal Malignancies Conducted in the United States

  • D. L. Kisner
  • P. S. Schein
  • J. S. Macdonald
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 79)


Gastrointestinal tract cancer is the leading cause of cancer mortality in the United States, causing more than 100,000 deaths a year. Approximately 99,000 new cases and 49,000 deaths occur annually from large-bowel cancers alone [37]. These figures have remained virtually unchanged in the last three decades. Carcinoma of the pancreas is increasing in incidence in the United States and is currently the fourth most common cause of cancer death. More than 21,000 cases occur annually with virtually all patients eventually dying of their disease [37]. Carcinoma of the stomach has progressively decreased in incidence in the United States over the past four decades but still accounts for more than 14,000 deaths annually [37]. Because of the high rate of primary unresectability and recurrence after resection most patients at some time in their course become candidates for therapy directed at locoregional or metastatic disease. Recent clinical research in the United States has been aimed at identifying and confirming the activity of chemotherapy or combined modality treatments for patients with advanced metastatic disease for future application in the locoregional or surgical adjuvant setting. The purpose of this report is to highlight the pertinent recent data and outline ongoing studies of interest.


Gastric Cancer Clin Oncol Eastern Cooperative Oncology Group Advanced Gastric Cancer Advanced Pancreatic Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aberhalden RT, Bukowski RM, Groppe CW et al. (1977) Streptozotocin (STZ) and 5-fluorouracil (5-FU) with and without mitomycin-C ( Mito) in the treatment of pancreatic adenocarcinomas. Proc Am Soc Clin Oncol 18: 301Google Scholar
  2. 2.
    Baker LH, Izbicki DO, Vaitkevicius VK (1976) Phase II study of porfiromycin versus mitomycin-C utilizing acute intermittent schedules. Med Pediatr Oncol 2: 207–213PubMedCrossRefGoogle Scholar
  3. 3.
    Bitran J, Desser R, Kozloff M, Billings A (1979) Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil, adriamycin, and mitomycin-C ( FAM ). Cancer Treat Rep 63: 2049–2051PubMedGoogle Scholar
  4. 4.
    Buroker T, Kim PN, Heilbrun L et al. (1978) 5-FU infusion with mitomycin-C (MMC) vs 5-FU infusion with methyl-CCNU ( Me) in the treatment of upper gastrointestinal cancer. Proc ASCO 19: 310Google Scholar
  5. 5.
    Carter SK (1976) Large bowel cancer - the current status of treatment. J Natl Cancer Inst 53: 3–10Google Scholar
  6. 6.
    Carter SK, Comis RL (1975) Adenocarcinoma of the pancreas, prognostic variables, and criteria of response in cancer therapy. In: Staquet MJ (ed) Prognostic factors and criteria of response in cancer therapy. Raven Press, New York, pp 237–253Google Scholar
  7. 7.
    Comis RL, Carter SK (1974) Integration of chemotherapy into combined modality treatment of solid tumors. III. Gastric cancer. Cancer Treat Rev 1: 221–228CrossRefGoogle Scholar
  8. 8.
    Douglass HO, Lavin PT, Moertel CG (1976) Nitrosoureas, useful agents for treatment of advanced gastrointestinal cancer. Cancer Treat Rep 60: 769–780PubMedGoogle Scholar
  9. 9.
    Engstrom P, Macintyre J, Douglass H, Carbone P (1978) Combination chemotherapy of advanced bowel cancer. Proc Am Soc Clin Oncol 19: 384Google Scholar
  10. 10.
    Falkson G, van Eden EB, Falkson HC (1974) Fluorouracil, imidazole carboxamide, dimethyl/triazeno, vincristine, and bis-chloroethyl nitrosourea in colon cancer. Cancer 33: 1207–1209PubMedCrossRefGoogle Scholar
  11. 11.
    Gastrointestinal Tumor Study Group (1979) A multiinstitutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. Ann Surg 189: 205–208Google Scholar
  12. 12.
    Gastrointestinal Tumor Study Group (1979) Phase II–III studies in advanced gastric cancer. Cancer Treat Rep 63: 1871–1876Google Scholar
  13. 13.
    Hoth D, Butler T, Winokur S et al. (1978) Phase II study of chlorozotocin. Proc Am Soc Clin Oncol 19: 381Google Scholar
  14. 14.
    Jones R, Cooperating Investigators (1959) Mitomycin-C a preliminary report of studies of human pharmacology and initial therapeutic trial. Cancer Chemother Rep 2: 3–7Google Scholar
  15. 15.
    Kemeny N, Yagoda A, Braun D, Golbey R (1980) Therapy for metastatic colorectal cancer with a combination of methyl-CCNU, 5-fluorouracil, vincristine and streptozotocin ( MOF-Strept ). Cancer 45: 876–881PubMedCrossRefGoogle Scholar
  16. 16.
    Kemeny N, Yagoda A, Golbey R (1980) A prospective randomized study of methyl-CCNU, 5 fluorouracil, and vincristine (MOF) vs MOF plus streptozotocin ( MOF-Strep) in patients with metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 21: 417Google Scholar
  17. 17.
    Kovach JS, Moertel CG, Schutt AJ (1974) A controlled study of combined l,3-bis(2- chloroethyl)-l-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer. Cancer 33: 563–567PubMedCrossRefGoogle Scholar
  18. 18.
    Lacave AJ, Izarzugaza I, Gracia Marco JM (to be published) Phase II clinical study of cisplatin in gastric cancer resistant to chemotherapy. Cancer Treat RepGoogle Scholar
  19. 19.
    Lokich JJ, Skarin AT (1972) Combination therapy with 5-fluorouracil (5-FU) and l,3-bis(2- chloroethyl)-l-nitrosourea ( BCNU) for disseminated gastrointestinal carcinoma. Cancer Chemother Rep 56: 653–657PubMedGoogle Scholar
  20. 20.
    Macdonald JS, Schein P, Ueno W, Woolley PV (1979) 5-Fluorouracil, mitomycin-C and adriamycin-FAM: a new combination chemotherapy program for advanced gastric carcinoma. Cancer 44: 42–47PubMedCrossRefGoogle Scholar
  21. 21.
    Marciniak TA, Moertel CG, Schutt AJ, Hahn RG, Reitemeier RJ (1975) A phase II study of ICRF-159 (NSC-1299436) in advanced colorectal carcinoma. Cancer Chemother Rep 59: 7619Google Scholar
  22. 22.
    McCreary RN, Moertel CG, Schutt AJ et al. (1977) A phase II study of triazinate (NSC-139105) in advanced colorectal carcinoma. Cancer 40: 9–13PubMedCrossRefGoogle Scholar
  23. 23.
    Mittelman A for the Gastrointestinal Tumor Study Group (to be published) Adjuvant chemotherapy + radiotherapy to rectal cancer. In: Gérard A (ed) Progress and perspectives in the treatment of gastrointestinal tumors. Pergamon, Oxford New YorkGoogle Scholar
  24. 24.
    Moertel CG (1973) Therapy of advanced gastrointestinal cancer with the nitosoureas. Cancer Chemother Rep 4: 27–34Google Scholar
  25. 25.
    Moertel CG (1975) Clinical management of advanced gastrointestinal cancer. Cancer 36: 675 - 682PubMedCrossRefGoogle Scholar
  26. 26.
    Moertel CG, Lavin PT (1977) An evaluation of 5-FU, nitrosourea and “Lactone” combinations in the therapy of upper gastrointestinal cancer. Proc AACR and Am Soc Clin Oncol 18: 344Google Scholar
  27. 27.
    Moertel CG, Lavin PT (1979) Phase II–III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63: 1863–1869PubMedGoogle Scholar
  28. 28.
    Moertel CG, Reitemeier RJ, Hahn RG (1969) Therapy with the fluorinated pyrinidines. In: Moertel CG, Reitemeier RJ (eds) Advanced gastrointestinal cancer. Harper & Row, New York, pp 86–107Google Scholar
  29. 29.
    Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG (1972) A phase II study of l-(2-chloroethyl)3-cyclohexyl-l-nitrosourea (CCNU, NSC-9037) in the palliative management of advanced gastrointestinal cancer. Cancer Res 32: 1278–1279PubMedGoogle Scholar
  30. 30.
    Moertel CG, Schutt AJ, Hahn RG, Reitemeier RJ (1975) Therapy of advanced gastrointestinal cancer with a combination of 5-FU, methyl-CCNU and vincristine. J Natl Cancer Inst 54: 69–71PubMedGoogle Scholar
  31. 31.
    Moertel CG, Mittelman J, Bakermeier RF, Engstrom P, Hanely JA (1976) Sequential and combination chemotherapy of advanced gastric cancer. Cancer 38: 678–682PubMedCrossRefGoogle Scholar
  32. 32.
    Moore GF, Bross IDJ, Ausman R (1968) Effects of mitomycin-C (NSC 26980) in 346 patients with advanced cancer. Cancer Chemother Rep 52: 675–684PubMedGoogle Scholar
  33. 33.
    Panettiere F, Heilbrun L (1979) Comparison of two different combinations of adriamycin, mitomycin-C, and 5-FU in the management of gastric carcinoma, a SWOG study. Proc AACR and Am Soc Clin Oncol 20: 315Google Scholar
  34. 34.
    Rakieten N, Rakieten ML, Nadkarni MW (1963) Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 29: 91–98Google Scholar
  35. 35.
    Schein PS, Lavin PT, Moertel CG et al. (1978) Randomized phase II clinical trial of adriamycin in advanced measurable pancreatic carcinoma: a Gastrointestinal Tumor Study Group report. Cancer 42: 19–22PubMedCrossRefGoogle Scholar
  36. 36.
    Schein PS, Novak J for the Gastrointestinal Tumor Study Group (1980) Combined modality therapy ( XRT-chemo) versus chemotherapy alone for locally unresectable gastric cancer. Proc Am Soc Clin Oncol 21: 419Google Scholar
  37. 37.
    Silverberg E (1977) Cancer statistics. CA 27: 26–41PubMedCrossRefGoogle Scholar
  38. 38.
    Smith FP, Macdonald JS, Woolley PV et al. (1979) Phase II evaluation of FAM in advanced pancreatic cancer. Proc Am Soc Clin Oncol 20: 415Google Scholar
  39. 39.
    Smith F, Woolley P, Rogers C, Ornitz R, Schein P (1980) Fast neutron (FN) for locally advanced pancreatic carcinoma ( LAP ). Proc Am Soc Clin Oncol 21: 367Google Scholar
  40. 40.
    Waddell WR (1973) Chemotherapy for carcinoma of the pancreas. Surgery 74: 420–429PubMedGoogle Scholar
  41. 41.
    Wiggans G, Woolley PV, Macdonald JS et al. (1978) Phase II trial of streptozotocin, mitomycin-C, and 5-fluorouracil (5MF) in the treatment of advanced pancreatic cancer. Cancer 41: 387–391PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1981

Authors and Affiliations

  • D. L. Kisner
    • 1
  • P. S. Schein
    • 1
  • J. S. Macdonald
    • 1
  1. 1.Division of Cancer Treatment, Cancer Therapy Evaluation ProgramNational Cancer InstituteBethesdaUSA

Personalised recommendations